Document is current
Any future updates will be listed below
-
Authors
Saez-Ayala, Magali https://orcid.org/0000-0002-8726-0053
Hoffer, Laurent https://orcid.org/0000-0003-1906-7128
Abel, Sébastien
Ben Yaala, Khaoula
Sicard, Benoit
Andrieu, Guillaume P. https://orcid.org/0000-0003-0289-4952
Latiri, Mehdi
Davison, Emma K. https://orcid.org/0000-0002-9280-2742
Ciufolini, Marco A.
Brémond, Paul https://orcid.org/0000-0001-5263-3473
Rebuffet, Etienne https://orcid.org/0000-0001-5192-907X
Roche, Philippe https://orcid.org/0000-0002-5580-0588
Derviaux, Carine
Voisset, Edwige https://orcid.org/0000-0002-0943-4847
Montersino, Camille https://orcid.org/0000-0001-7024-5327
Castellano, Remy
Collette, Yves https://orcid.org/0000-0001-5359-7099
Asnafi, Vahid
Betzi, Stéphane https://orcid.org/0000-0001-5935-5058
Dubreuil, Patrice https://orcid.org/0000-0003-1155-1150
Combes, Sébastien https://orcid.org/0000-0002-8213-2407
Morelli, Xavier https://orcid.org/0000-0001-8101-7901
- License Information
-
More Information
Article History
Received: 22 September 2022
Accepted: 11 May 2023
First Online: 29 May 2023
Competing interests
: M.S.A., L.H., S.A., K.B.Y., B.S., P.B., E.R., P.R., S.B., P.D., S.C., and X.M. are inventors of a patent entitled “Deoxycytidine kinase inhibitors” filed by the Centre National de la Recherche Scientifique on January 17, 2022 (EP 22 30 5038). The invention relates to the deoxycytidine kinase inhibitors and their uses for treating cancer. The remaining authors declare no competing interests.
: All animal experiments were performed using standard methods in agreement with the French Guidelines for animal handling and approved by the local ethics committee (CREMEAS, CEEA 35) according to the APAFiS procedure (agreement numbers APAFIS#6743 and APAFIS#19987). Patients were enrolled in the GRAALL-2003-2005 trials (registered on as follows: GRAALL-2003, #NCT00222027; GRAALL-2005, #NCT00327678). Patient samples were collected after informed consent according to the Declaration of Helsinki.
